首页 > 最新文献

Journal of Pathology and Translational Medicine最新文献

英文 中文
What's new in kidney tumor pathology 2022: WHO 5th edition updates. 肾肿瘤病理学最新进展2022:WHO第5版更新。
IF 2.4 Q2 Medicine Pub Date : 2022-11-01 Epub Date: 2022-09-08 DOI: 10.4132/jptm.2022.08.16
Maria Tretiakova

The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) introduces significant changes relevant to daily practice, especially in the completely restructured renal cell tumor chapters. Herein we highlight the most important diagnostic updates of known kidney tumor types, new and molecularly defined entities and emerging/provisional entities.

世卫组织泌尿和男性生殖器肿瘤分类(2022年)第5版引入了与日常实践相关的重大变化,特别是在完全重组的肾细胞肿瘤章节中。在这里,我们重点介绍了已知肾肿瘤类型、新的和分子定义的实体以及新兴/临时实体的最重要的诊断更新。
{"title":"What's new in kidney tumor pathology 2022: WHO 5th edition updates.","authors":"Maria Tretiakova","doi":"10.4132/jptm.2022.08.16","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.16","url":null,"abstract":"<p><p>The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) introduces significant changes relevant to daily practice, especially in the completely restructured renal cell tumor chapters. Herein we highlight the most important diagnostic updates of known kidney tumor types, new and molecularly defined entities and emerging/provisional entities.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/eb/jptm-2022-08-16.PMC9682217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40353941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma 原发性和继发性乳腺血管肉瘤的临床病理和免疫组织化学研究
IF 2.4 Q2 Medicine Pub Date : 2022-10-26 DOI: 10.4132/jptm.2022.08.31
E. Abada, H. Jang, Seong-Min Kim, R. Ali-Fehmi, S. Bandyopadhyay
Background We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). Methods This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records. Results Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450). Conclusions BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study.
背景我们旨在研究原发性和继发性乳腺血管肉瘤(BAS)的临床病理和免疫组织化学(IHC)(CD117、c-Myc和p53)特征以及总生存率。方法对我院1997年至2020年间诊断的BAS病例进行回顾性研究。对苏木精和伊红染色的载玻片的肿瘤形态、边缘状态和淋巴结转移进行了回顾。对11个活组织块进行CD117、p53、D2-40、CD31和c-Myc IHC染色。从电子病历中获得了其他临床信息。结果发现BAS患者17例。其中,5例(29%)为原发性BAS,12例(71%)为继发性BAS。诊断为原发性BAS的中位年龄为36岁。诊断为继发性BAS的中位年龄为67岁。放疗后继发BAS发展的中位时间为6.5年(范围为2至12年)。原发性和继发性BAS在检查的几个组织病理学参数方面没有显著差异,包括组织学分级、坏死、有丝分裂计数、淋巴结转移和阳性肿瘤边缘。原发性BAS和继发性BAS的IHC表达CD117、p53、D2-40、CD31和c-Myc也没有差异。在21个月的中位随访中,原发性BAS有两例(40%)报告死亡,继发性BAS有三例(25%)报告死亡。然而,两组之间的生存率差异没有统计学意义(危险比为0.51;95%置信区间为0.09至3.28;p=.450)。结论BAS是一种罕见的侵袭性疾病。在本研究中,原发性和继发性BAS之间没有发现组织学、IHC(CD117、c-Myc和p53)或生存差异。
{"title":"A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma","authors":"E. Abada, H. Jang, Seong-Min Kim, R. Ali-Fehmi, S. Bandyopadhyay","doi":"10.4132/jptm.2022.08.31","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.31","url":null,"abstract":"Background We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). Methods This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records. Results Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450). Conclusions BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study.","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42677402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Current status of cytopathology practice in Korea: impact of the coronavirus pandemic on cytopathology practice 韩国细胞病理学实践现状:冠状病毒大流行对细胞病理学的影响
IF 2.4 Q2 Medicine Pub Date : 2022-10-26 DOI: 10.4132/jptm.2022.09.21
Soon Auck Hong, H. Jung, S. S. Kim, Min-Sun Jin, J. Pyo, J. Jeong, Younghee Choi, G. Gong, Y. Chong
Background The Continuous Quality Improvement program for cytopathology in 2020 was completed during the coronavirus pandemic. In this study, we report the result of the quality improvement program. Methods Data related to cytopathology practice from each institute were collected and processed at the web-based portal. The proficiency test was conducted using glass slides and whole-slide images (WSIs). Evaluation of the adequacy of gynecology (GYN) slides from each institution and submission of case glass slides and WSIs for the next quality improvement program were performed. Results A total of 214 institutions participated in the annual cytopathology survey in 2020. The number of entire cytopathology specimens was 8,220,650, a reduction of 19.0% from the 10,111,755 specimens evaluated in 2019. Notably, the number of respiratory cytopathology specimens, including sputum and bronchial washing/ brushing significantly decreased by 86.9% from 2019, which could be attributed to the global pandemic of coronavirus disease. The ratio of cases with atypical squamous cells to squamous intraepithelial lesions was 4.10. All participating institutions passed the proficiency test and the evaluation of adequacy of GYN slides. Conclusions Through the Continuous Quality Improvement program, the effect of coronavirus disease 2019 pandemic, manifesting with a reduction in the number of cytologic examinations, especially in respiratory-related specimen has been identified. The Continuous Quality Improvement Program of the Korean Society for Cytopathology can serve as the gold standard to evaluate the current status of cytopathology practice in Korea.
背景2020年细胞病理学持续质量改进计划是在冠状病毒大流行期间完成的。在这项研究中,我们报告了质量改进计划的结果。方法在网络门户网站上收集和处理各研究所的细胞病理学实践相关数据。使用玻璃载玻片和全载玻片图像(WSI)进行能力测试。对每个机构的妇科(GYN)载玻片的充分性进行评估,并为下一个质量改进计划提交病例玻璃载玻片和WSI。结果共有214家机构参加了2020年的年度细胞病理学调查。整个细胞病理学标本的数量为8220650个,比2019年评估的10111755个标本减少了19.0%。值得注意的是,包括痰液和支气管冲洗/刷牙在内的呼吸道细胞病理学标本数量比2019年显著减少了86.9%,这可能归因于冠状病毒疾病的全球大流行。非典型鳞状细胞与鳞状上皮内病变的病例比例为4.10。所有参与机构都通过了能力测试和妇科幻灯片的充分性评估。结论通过持续质量改进计划,已经确定了2019冠状病毒病大流行的影响,表现为细胞学检查次数的减少,特别是在呼吸道相关标本中。韩国细胞病理学会的持续质量改进计划可以作为评估韩国细胞病理学实践现状的金标准。
{"title":"Current status of cytopathology practice in Korea: impact of the coronavirus pandemic on cytopathology practice","authors":"Soon Auck Hong, H. Jung, S. S. Kim, Min-Sun Jin, J. Pyo, J. Jeong, Younghee Choi, G. Gong, Y. Chong","doi":"10.4132/jptm.2022.09.21","DOIUrl":"https://doi.org/10.4132/jptm.2022.09.21","url":null,"abstract":"Background The Continuous Quality Improvement program for cytopathology in 2020 was completed during the coronavirus pandemic. In this study, we report the result of the quality improvement program. Methods Data related to cytopathology practice from each institute were collected and processed at the web-based portal. The proficiency test was conducted using glass slides and whole-slide images (WSIs). Evaluation of the adequacy of gynecology (GYN) slides from each institution and submission of case glass slides and WSIs for the next quality improvement program were performed. Results A total of 214 institutions participated in the annual cytopathology survey in 2020. The number of entire cytopathology specimens was 8,220,650, a reduction of 19.0% from the 10,111,755 specimens evaluated in 2019. Notably, the number of respiratory cytopathology specimens, including sputum and bronchial washing/ brushing significantly decreased by 86.9% from 2019, which could be attributed to the global pandemic of coronavirus disease. The ratio of cases with atypical squamous cells to squamous intraepithelial lesions was 4.10. All participating institutions passed the proficiency test and the evaluation of adequacy of GYN slides. Conclusions Through the Continuous Quality Improvement program, the effect of coronavirus disease 2019 pandemic, manifesting with a reduction in the number of cytologic examinations, especially in respiratory-related specimen has been identified. The Continuous Quality Improvement Program of the Korean Society for Cytopathology can serve as the gold standard to evaluate the current status of cytopathology practice in Korea.","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48053889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea BRAF VE1免疫组织化学在非小细胞肺癌中的作用:韩国15名病理学家的多机构研究
IF 2.4 Q2 Medicine Pub Date : 2022-10-26 DOI: 10.4132/jptm.2022.08.22
S. Chang, Yoon-La Choi, H. Shim, G. Lee, S. Ha
Background Next-generation sequencing (NGS) is an approved test to select patients for BRAF V600E targeted therapy in Korea. However, the high cost, long turnaround times, and the need for sophisticated equipment and skilled personnel limit the use of NGS in daily practice. Immunohistochemistry (IHC) is a rapid and relatively inexpensive assay available in most laboratories. Therefore, in this study, we evaluate the usefulness of BRAF VE1 IHC in terms of predictive value and interobserver agreement in non–small cell lung cancers (NSCLCs). Methods A total of 30 cases with known BRAF mutation status were selected, including 20 cases of lung adenocarcinomas, six cases of colorectal adenocarcinomas, and four cases of papillary thyroid carcinomas. IHC for BRAF V600E was carried out using the VE1 antibody. Fifteen pathologists independently scored both the staining intensity and the percentage of tumor cell staining on whole slide images. Results In the lung adenocarcinoma subset, interobserver agreement for the percentage of tumor cell staining and staining intensity was good (percentage of tumor cell staining, intraclass correlation coefficient = 0.869; staining intensity, kappa = 0.849). The interobserver agreement for the interpretation using the cutoff of 40% was almost perfect in the entire study group and the lung adenocarcinoma subset (kappa = 0.815). Sensitivity, specificity, positive predictive value, and negative predictive value of BRAF VE1 IHC were 80.0%, 90.0%, 88.9%, and 81.8%, respectively. Conclusions BRAF VE1 IHC could be a screening test for the detection of BRAF V600E mutation in NSCLC. However, further studies are needed to optimize the protocol and to establish and validate interpretation criteria for BRAF VE1 IHC.
在韩国,下一代测序(NGS)是选择BRAF V600E靶向治疗患者的一种被批准的检测方法。然而,高成本、长周转时间以及对精密设备和熟练人员的需求限制了NGS在日常实践中的使用。免疫组织化学(IHC)是一种快速且相对便宜的检测方法,大多数实验室都可以使用。因此,在本研究中,我们评估了BRAF VE1 IHC在非小细胞肺癌(nsclc)中的预测价值和观察者间一致性的有用性。方法选取已知BRAF突变状态的30例患者,其中肺腺癌20例,结直肠腺癌6例,甲状腺乳头状癌4例。采用VE1抗体对BRAF V600E进行免疫组化检测。15名病理学家独立对整个切片图像的染色强度和肿瘤细胞染色百分比进行评分。结果在肺腺癌亚群中,肿瘤细胞染色百分比和染色强度的观察者间一致性较好(肿瘤细胞染色百分比,类内相关系数= 0.869;染色强度,kappa = 0.849)。在整个研究组和肺腺癌亚组中,使用40%截断值解释的观察者间一致性几乎是完美的(kappa = 0.815)。BRAF VE1 IHC的敏感性为80.0%,特异性为90.0%,阳性预测值为88.9%,阴性预测值为81.8%。结论BRAF V600E基因IHC可作为非小细胞肺癌BRAF V600E基因突变的筛查方法。然而,需要进一步的研究来优化方案,并建立和验证BRAF VE1 IHC的解释标准。
{"title":"Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea","authors":"S. Chang, Yoon-La Choi, H. Shim, G. Lee, S. Ha","doi":"10.4132/jptm.2022.08.22","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.22","url":null,"abstract":"Background Next-generation sequencing (NGS) is an approved test to select patients for BRAF V600E targeted therapy in Korea. However, the high cost, long turnaround times, and the need for sophisticated equipment and skilled personnel limit the use of NGS in daily practice. Immunohistochemistry (IHC) is a rapid and relatively inexpensive assay available in most laboratories. Therefore, in this study, we evaluate the usefulness of BRAF VE1 IHC in terms of predictive value and interobserver agreement in non–small cell lung cancers (NSCLCs). Methods A total of 30 cases with known BRAF mutation status were selected, including 20 cases of lung adenocarcinomas, six cases of colorectal adenocarcinomas, and four cases of papillary thyroid carcinomas. IHC for BRAF V600E was carried out using the VE1 antibody. Fifteen pathologists independently scored both the staining intensity and the percentage of tumor cell staining on whole slide images. Results In the lung adenocarcinoma subset, interobserver agreement for the percentage of tumor cell staining and staining intensity was good (percentage of tumor cell staining, intraclass correlation coefficient = 0.869; staining intensity, kappa = 0.849). The interobserver agreement for the interpretation using the cutoff of 40% was almost perfect in the entire study group and the lung adenocarcinoma subset (kappa = 0.815). Sensitivity, specificity, positive predictive value, and negative predictive value of BRAF VE1 IHC were 80.0%, 90.0%, 88.9%, and 81.8%, respectively. Conclusions BRAF VE1 IHC could be a screening test for the detection of BRAF V600E mutation in NSCLC. However, further studies are needed to optimize the protocol and to establish and validate interpretation criteria for BRAF VE1 IHC.","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48354443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Papillary and medullary thyroid carcinomas coexisting in the same lobe, first suspected based on fine-needle aspiration cytology: a case report. 甲状腺乳头状癌和髓样癌共存于同一叶,首次怀疑基于细针穿刺细胞学:1例报告。
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-09-13 DOI: 10.4132/jptm.2022.08.03
Hyun Hee Koh, Young Lyun Oh

Because different types of thyroid malignancies have distinct embryological origins, coexisting tumors are rarely observed. We describe a coexisting papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) first suspected by fine-needle aspiration cytology (FNAC). A 57-year-old female presented with an irregular mass in the right thyroid lobe. The cytopathologic findings of fine-needle aspiration showed two components: a papillary-like arrangement consisting of cells with pale enlarged nuclei indicative of PTC and loose clusters comprised of oval cells with granular chromatin indicative of MTC. The diagnosis of a coexisting PTC and MTC was initially confirmed by calcitonin immunocytochemistry and later after total thyroidectomy. Although some surgical case reports of PTC and MTC coexisting in either the same or different lobes have been documented, a case suspected by FNAC before the surgery has rarely been reported. Because appropriate treatment and prognosis of PTC and MTC are different, cytopathologists should be aware of this rare entity.

由于不同类型的甲状腺恶性肿瘤具有不同的胚胎起源,因此很少观察到共存的肿瘤。我们描述了一种共存的甲状腺乳头状癌(PTC)和甲状腺髓样癌(MTC),首次被细针穿刺细胞学(FNAC)怀疑。一位57岁的女性在右侧甲状腺叶出现不规则肿块。细针穿刺的细胞病理学结果显示两个组成部分:乳头状排列,由细胞核苍白增大的细胞组成,表明PTC;松散的簇状排列,由染色质颗粒状的椭圆形细胞组成,表明MTC。PTC和MTC共存的诊断最初通过降钙素免疫细胞化学证实,后来在甲状腺全切除术后确诊。虽然有一些手术病例报告PTC和MTC共存于同一或不同的叶,但在手术前怀疑有FNAC的病例很少报道。由于PTC和MTC的适当治疗和预后不同,细胞病理学家应该注意这种罕见的实体。
{"title":"Papillary and medullary thyroid carcinomas coexisting in the same lobe, first suspected based on fine-needle aspiration cytology: a case report.","authors":"Hyun Hee Koh,&nbsp;Young Lyun Oh","doi":"10.4132/jptm.2022.08.03","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.03","url":null,"abstract":"<p><p>Because different types of thyroid malignancies have distinct embryological origins, coexisting tumors are rarely observed. We describe a coexisting papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) first suspected by fine-needle aspiration cytology (FNAC). A 57-year-old female presented with an irregular mass in the right thyroid lobe. The cytopathologic findings of fine-needle aspiration showed two components: a papillary-like arrangement consisting of cells with pale enlarged nuclei indicative of PTC and loose clusters comprised of oval cells with granular chromatin indicative of MTC. The diagnosis of a coexisting PTC and MTC was initially confirmed by calcitonin immunocytochemistry and later after total thyroidectomy. Although some surgical case reports of PTC and MTC coexisting in either the same or different lobes have been documented, a case suspected by FNAC before the surgery has rarely been reported. Because appropriate treatment and prognosis of PTC and MTC are different, cytopathologists should be aware of this rare entity.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/b2/jptm-2022-08-03.PMC9510044.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammation and tissue remodeling contribute to fibrogenesis in stricturing Crohn's disease: image processing and analysis study. 炎症和组织重塑促进狭窄性克罗恩病的纤维生成:图像处理和分析研究。
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-07-04 DOI: 10.4132/jptm.2022.05.18
Mustafa Erdem Arslan, Rupinder Brar, Lianna Goetz, Dipti Karamchandani, Michael W Mikula, Kyle Hodge, Hua Li, Sangtae Ahn, Hwajeong Lee

Background: Inflammation and structural remodeling may contribute to fibrogenesis in Crohn's disease (CD). We quantified the immunoexpression of calretinin, CD34, and calprotectin as a surrogate for mucosal innervation, telocytes (interstitial cells playing a role in networking), and inflammation, respectively, and correlated them with bowel alterations in stricturing CD.

Methods: Primary resection specimens for ileal CD (n = 44, 31 stricturing CD, 13 inflammatory CD) were identified. Left-sided ulcerative colitis and trauma cases were used as controls. Proximal and distal margin and middle (diseased) sections were stained for calretinin, CD34, and calprotectin. Microscopic images were captured from the mucosa (calretinin), submucosa (calprotectin), and myenteric plexus (CD34), and the immunostaining was quantified using image processing and analysis. Bowel thickness at the corresponding sections were measured and correlated with the amount of immunoexpression.

Results: A total of 2,037 images were analyzed. In stricturing CD, submucosal alteration/thickening at the stricture site correlated with calprotectin staining and inversely correlated with calretinin staining at the proximal margin. Muscularis propria alteration/thickening at the stricture site correlated with mucosal calretinin staining at the proximal margin. Submucosal alteration/thickening at the proximal margin correlated with calretinin and CD34 staining at the proximal margin and inversely correlated with CD34 staining at the stricture site. Calretinin immunostaining at the distal margin was significantly higher in stricturing CD than the controls.

Conclusions: Inflammation and tissue remodeling appear to contribute to fibrogenesis in stricturing CD. Increased mucosal calretinin immunostaining distal to the diseased segment could be helpful in diagnosing CD in the right clinical context.

背景:炎症和结构重塑可能有助于克罗恩病(CD)的纤维生成。我们分别量化了calretinin、CD34和calprotectin的免疫表达,作为粘膜神经分布、远端细胞(在网络中起作用的间质细胞)和炎症的替代指标,并将它们与狭窄性CD的肠道改变联系起来。方法:鉴定了44例回肠CD (n = 44, 31例狭窄性CD, 13例炎症性CD)的初步切除标本。左侧溃疡性结肠炎和创伤病例作为对照。近端、远端边缘和中间(病变)切片染色calretinin, CD34和calprotectin。显微图像采集粘膜(calretinin)、粘膜下层(calprotectin)和肌丛(myenteric plexus) (CD34),通过图像处理和分析定量免疫染色。测量相应切片的肠厚,并与免疫表达量相关。结果:共分析2037张图像。在狭窄性CD中,狭窄部位的粘膜下改变/增厚与钙保护蛋白染色相关,与近缘钙保护蛋白染色负相关。狭窄部位固有肌层改变/增厚与近缘粘膜calcalin染色相关。近缘粘膜下改变/增厚与近缘calretinin和CD34染色相关,与狭窄部位CD34染色呈负相关。狭窄性CD远端缘Calretinin免疫染色明显高于对照组。结论:炎症和组织重塑似乎有助于狭窄性乳糜泻的纤维生成。病变远端粘膜calretinin免疫染色增加可能有助于在正确的临床背景下诊断乳糜泻。
{"title":"Inflammation and tissue remodeling contribute to fibrogenesis in stricturing Crohn's disease: image processing and analysis study.","authors":"Mustafa Erdem Arslan,&nbsp;Rupinder Brar,&nbsp;Lianna Goetz,&nbsp;Dipti Karamchandani,&nbsp;Michael W Mikula,&nbsp;Kyle Hodge,&nbsp;Hua Li,&nbsp;Sangtae Ahn,&nbsp;Hwajeong Lee","doi":"10.4132/jptm.2022.05.18","DOIUrl":"https://doi.org/10.4132/jptm.2022.05.18","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and structural remodeling may contribute to fibrogenesis in Crohn's disease (CD). We quantified the immunoexpression of calretinin, CD34, and calprotectin as a surrogate for mucosal innervation, telocytes (interstitial cells playing a role in networking), and inflammation, respectively, and correlated them with bowel alterations in stricturing CD.</p><p><strong>Methods: </strong>Primary resection specimens for ileal CD (n = 44, 31 stricturing CD, 13 inflammatory CD) were identified. Left-sided ulcerative colitis and trauma cases were used as controls. Proximal and distal margin and middle (diseased) sections were stained for calretinin, CD34, and calprotectin. Microscopic images were captured from the mucosa (calretinin), submucosa (calprotectin), and myenteric plexus (CD34), and the immunostaining was quantified using image processing and analysis. Bowel thickness at the corresponding sections were measured and correlated with the amount of immunoexpression.</p><p><strong>Results: </strong>A total of 2,037 images were analyzed. In stricturing CD, submucosal alteration/thickening at the stricture site correlated with calprotectin staining and inversely correlated with calretinin staining at the proximal margin. Muscularis propria alteration/thickening at the stricture site correlated with mucosal calretinin staining at the proximal margin. Submucosal alteration/thickening at the proximal margin correlated with calretinin and CD34 staining at the proximal margin and inversely correlated with CD34 staining at the stricture site. Calretinin immunostaining at the distal margin was significantly higher in stricturing CD than the controls.</p><p><strong>Conclusions: </strong>Inflammation and tissue remodeling appear to contribute to fibrogenesis in stricturing CD. Increased mucosal calretinin immunostaining distal to the diseased segment could be helpful in diagnosing CD in the right clinical context.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/71/jptm-2022-05-18.PMC9510042.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors. 特殊的富含at序列结合蛋白2 (SATB2)在成骨性和非成骨性骨和软组织肿瘤鉴别诊断中的作用。
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-09-13 DOI: 10.4132/jptm.2022.07.11
Sharon Milton, Anne Jennifer Prabhu, V T K Titus, Rikki John, Selvamani Backianathan, Vrisha Madhuri

Background: The diagnosis of osteosarcoma (OSA) depends on clinicopathological and radiological correlation. A biopsy is considered the gold standard for OSA diagnosis. However, since OSA is a great histological mimicker, diagnostic challenges exist. Immunohistochemistry (IHC) can serve as an adjunct for the histological diagnosis of OSA. Special AT-rich sequence-binding protein 2 (SATB2) was recently described as a reliable adjunct immunohistochemical marker for the diagnosis of OSA.

Methods: We investigated the IHC expression of SATB2 in 95 OSA and 100 non-osteogenic bone and soft tissue tumors using a monoclonal antibody (clone EPNCIR30A). The diagnostic utility of SATB2 and correlation with clinicopathological parameters were analyzed.

Results: SATB2 IHC was positive in 88 out of 95 cases (92.6%) of OSA and 50 out of 100 cases (50.0%) of primary non-osteogenic bone and soft tissue tumors. Of the 59 bone tumors, 37 cases (62.7%) were positive for SATB2, and of the 41 soft tissue tumors, 13 cases (31.7%) were positive for SATB2. The sensitivity of SATB2 as a diagnostic test was 92.6%, specificity 50%, positive predictive value 63.8%, and negative predictive value 87.7%.

Conclusions: Although SATB2 is a useful diagnostic marker for OSA, other clinical, histological and immunohistochemical features should be considered for the interpretation of SATB2.

背景:骨肉瘤(OSA)的诊断依赖于临床病理和影像学的相关性。活组织检查被认为是OSA诊断的金标准。然而,由于OSA是一个巨大的组织学模仿者,因此存在诊断挑战。免疫组织化学(IHC)可作为OSA组织学诊断的辅助手段。特殊的富含at的序列结合蛋白2 (SATB2)最近被描述为诊断OSA的可靠辅助免疫组织化学标志物。方法:采用单克隆抗体(克隆EPNCIR30A)检测95例OSA和100例非成骨性骨和软组织肿瘤中SATB2的IHC表达。分析SATB2的诊断价值及其与临床病理参数的相关性。结果:95例OSA患者中有88例(92.6%)SATB2 IHC阳性,100例原发性非成骨性骨及软组织肿瘤中有50例(50.0%)SATB2 IHC阳性。59例骨肿瘤中SATB2阳性37例(62.7%),41例软组织肿瘤中SATB2阳性13例(31.7%)。SATB2诊断敏感性为92.6%,特异性为50%,阳性预测值为63.8%,阴性预测值为87.7%。结论:虽然SATB2是OSA的一个有用的诊断标志物,但在解释SATB2时应考虑其他临床、组织学和免疫组织化学特征。
{"title":"Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors.","authors":"Sharon Milton,&nbsp;Anne Jennifer Prabhu,&nbsp;V T K Titus,&nbsp;Rikki John,&nbsp;Selvamani Backianathan,&nbsp;Vrisha Madhuri","doi":"10.4132/jptm.2022.07.11","DOIUrl":"https://doi.org/10.4132/jptm.2022.07.11","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis of osteosarcoma (OSA) depends on clinicopathological and radiological correlation. A biopsy is considered the gold standard for OSA diagnosis. However, since OSA is a great histological mimicker, diagnostic challenges exist. Immunohistochemistry (IHC) can serve as an adjunct for the histological diagnosis of OSA. Special AT-rich sequence-binding protein 2 (SATB2) was recently described as a reliable adjunct immunohistochemical marker for the diagnosis of OSA.</p><p><strong>Methods: </strong>We investigated the IHC expression of SATB2 in 95 OSA and 100 non-osteogenic bone and soft tissue tumors using a monoclonal antibody (clone EPNCIR30A). The diagnostic utility of SATB2 and correlation with clinicopathological parameters were analyzed.</p><p><strong>Results: </strong>SATB2 IHC was positive in 88 out of 95 cases (92.6%) of OSA and 50 out of 100 cases (50.0%) of primary non-osteogenic bone and soft tissue tumors. Of the 59 bone tumors, 37 cases (62.7%) were positive for SATB2, and of the 41 soft tissue tumors, 13 cases (31.7%) were positive for SATB2. The sensitivity of SATB2 as a diagnostic test was 92.6%, specificity 50%, positive predictive value 63.8%, and negative predictive value 87.7%.</p><p><strong>Conclusions: </strong>Although SATB2 is a useful diagnostic marker for OSA, other clinical, histological and immunohistochemical features should be considered for the interpretation of SATB2.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/b7/jptm-2022-07-11.PMC9510043.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of the characteristics of multiple human papillomavirus (HPV) infections identified using the BD Onclarity HPV assay and comparison with those of single HPV infection. 用BD Onclarity HPV检测方法鉴定多重人乳头瘤病毒(HPV)感染的特征评价,并与单一HPV感染的比较
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-09-13 DOI: 10.4132/jptm.2022.08.02
Jinhee Kim, Moonsik Kim, Ji Young Park

Background: Human papillomavirus (HPV) infection is a major cause of cervical cancer and associated precursor lesions. Multiple HPV genotype infections have been reported. However, their clinicopathological characteristics still remain elusive.

Methods: For this study, 814 consecutive patients who had undergone colposcopy and HPV genotyping test using BD Onclarity HPV assay were retrospectively selected. Clinicopathological parameters of multiple HPV infections were compared with those of single HPV infection.

Results: Multiple HPV infections were found in 110 out of 814 cases (13.5%). Multiple HPV infections were associated with a significantly higher incidence of high-grade intraepithelial lesions (HSILs) compared with single HPV infection. Other high-risk HPV genotypes, in addition to HPV 16, were found more frequently in the multiple HPV infections group; these included HPV 51, 52, 33/58, 56/59/66, and 35/39/68. No specific coinfection pattern was not identified. Additionally, the number of HPV genotypes in multiple HPV infections was not associated with the progression to HSIL or squamous cell carcinoma.

Conclusions: Multiple HPV infections have distinct clinicopathological characteristics (compared with single HPV infection). As their biological behavior is uncertain, close and frequent follow-up is warranted.

背景:人乳头瘤病毒(HPV)感染是宫颈癌及其相关前驱病变的主要原因。多种HPV基因型感染已被报道。然而,他们的临床病理特征仍然难以捉摸。方法:本研究回顾性选择814例连续接受阴道镜检查并使用BD Onclarity HPV检测进行HPV基因分型检测的患者。比较多发HPV感染与单一HPV感染的临床病理参数。结果:814例患者中有110例存在多发HPV感染,占13.5%。与单一HPV感染相比,多发HPV感染与高级别上皮内病变(HSILs)的发生率显著升高相关。除HPV 16外,其他高危HPV基因型在多发HPV感染组中更为常见;包括HPV 51、52、33/58、56/59/66和35/39/68。未发现特定的合并感染模式。此外,多重HPV感染中HPV基因型的数量与HSIL或鳞状细胞癌的进展无关。结论:多发HPV感染具有明显的临床病理特征(与单一HPV感染相比)。由于它们的生物学行为是不确定的,因此需要密切和频繁的随访。
{"title":"Evaluation of the characteristics of multiple human papillomavirus (HPV) infections identified using the BD Onclarity HPV assay and comparison with those of single HPV infection.","authors":"Jinhee Kim,&nbsp;Moonsik Kim,&nbsp;Ji Young Park","doi":"10.4132/jptm.2022.08.02","DOIUrl":"https://doi.org/10.4132/jptm.2022.08.02","url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV) infection is a major cause of cervical cancer and associated precursor lesions. Multiple HPV genotype infections have been reported. However, their clinicopathological characteristics still remain elusive.</p><p><strong>Methods: </strong>For this study, 814 consecutive patients who had undergone colposcopy and HPV genotyping test using BD Onclarity HPV assay were retrospectively selected. Clinicopathological parameters of multiple HPV infections were compared with those of single HPV infection.</p><p><strong>Results: </strong>Multiple HPV infections were found in 110 out of 814 cases (13.5%). Multiple HPV infections were associated with a significantly higher incidence of high-grade intraepithelial lesions (HSILs) compared with single HPV infection. Other high-risk HPV genotypes, in addition to HPV 16, were found more frequently in the multiple HPV infections group; these included HPV 51, 52, 33/58, 56/59/66, and 35/39/68. No specific coinfection pattern was not identified. Additionally, the number of HPV genotypes in multiple HPV infections was not associated with the progression to HSIL or squamous cell carcinoma.</p><p><strong>Conclusions: </strong>Multiple HPV infections have distinct clinicopathological characteristics (compared with single HPV infection). As their biological behavior is uncertain, close and frequent follow-up is warranted.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/2b/jptm-2022-08-02.PMC9510038.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma. R-CHOP治疗弥漫性大b细胞淋巴瘤中BLK表达的预后意义。
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-09-13 DOI: 10.4132/jptm.2022.07.26
Soyeon Choi, Yoo Jin Lee, Yunsuk Choi, Misung Kim, Hyun-Jung Kim, Ji Eun Kim, Sukjoong Oh, Seoung Wan Chae, Hee Jeong Cha, Jae-Cheol Jo

Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.

Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.

Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).

Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.

背景:本研究的目的是评估b细胞淋巴细胞激酶(BLK)表达对弥漫性大b细胞淋巴瘤(DLBCL)患者接受R-CHOP治疗后生存结果的预后意义。方法:回顾性分析两家三级转诊医院89例患者的病历。采用H-score半定量法检测BLK、SYK和CDK1的表达,检测BCL2和C-MYC的表达比例。结果:89例患者接受R-CHOP化疗作为一线化疗。BLK在肿瘤细胞中的表达率为39.2% (n = 34)。BLK表达状态与临床变量无显著相关性;然而,BLK在肿瘤细胞中的表达与C-MYC和BCL2的表达均显著相关(p = 0.003)。中位随访时间为60.4个月,BLK表达患者的5年无进展生存期(PFS)和总生存率(分别为49.8%和60.9%)显著低于无BLK表达患者(分别为77.3%和86.7%)。在PFS的多变量分析中,BLK阳性是一个独立的不良预后因素(危险比,2.208;P = .040)。结论:我们根据BLK在DLBCL中的表达来描述临床病理特征和生存结局。大约39%的DLBCL患者显示BLK阳性,这是接受R-CHOP化疗的患者预后不良的预测指标。
{"title":"Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma.","authors":"Soyeon Choi,&nbsp;Yoo Jin Lee,&nbsp;Yunsuk Choi,&nbsp;Misung Kim,&nbsp;Hyun-Jung Kim,&nbsp;Ji Eun Kim,&nbsp;Sukjoong Oh,&nbsp;Seoung Wan Chae,&nbsp;Hee Jeong Cha,&nbsp;Jae-Cheol Jo","doi":"10.4132/jptm.2022.07.26","DOIUrl":"https://doi.org/10.4132/jptm.2022.07.26","url":null,"abstract":"<p><strong>Background: </strong>The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.</p><p><strong>Methods: </strong>We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.</p><p><strong>Results: </strong>A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).</p><p><strong>Conclusions: </strong>Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b7/4c/jptm-2022-07-26.PMC9510039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Heterotopic mesenteric ossification: a report of two cases. 异位肠系膜骨化2例报告。
IF 2.4 Q2 Medicine Pub Date : 2022-09-01 Epub Date: 2022-09-13 DOI: 10.4132/jptm.2022.07.23
Hisham F Bahmad, Olga Lopez, Tyson Sutherland, Marisa Vinas, Kfir Ben-David, Lydia Howard, Robert Poppiti, Sarah Alghamdi

Heterotopic mesenteric ossification (HMO) is abnormal bone formation in tissues which usually do not undergo ossification. There are approximately 75 cases reported worldwide. We present two cases of HMO. The first case is that of a 39-year-old man who presented with abdominal pain and a computerized tomography scan of the abdomen and pelvis revealed an apple core lesion resulting in small bowel obstruction. The second case is that of a 36-year-old woman who presented 2 months after undergoing robotic gastric sleeve resection complaining of weakness and emesis. An esophagogram revealed kinking at the distal esophagus. Surgical resection was performed in both, yielding the diagnosis of HMO. There are various theories as to the pathophysiology of HMO, but no clearly defined mechanism has been established. Management should be conservative whenever possible to prevent further ossification with subsequent surgical intervention.

异位肠系膜骨化(HMO)是在通常不发生骨化的组织中发生的异常骨形成。全世界报告的病例约有75例。我们提出两例HMO病例。第一个病例是一名39岁的男性,他表现为腹痛,腹部和骨盆的计算机断层扫描显示苹果核病变导致小肠梗阻。第二个病例是一名36岁的女性,她在接受机器人胃袖切除术2个月后出现虚弱和呕吐。食道造影显示远端食道扭结。两例均行手术切除,诊断为HMO。关于HMO的病理生理有多种理论,但尚未建立明确的机制。治疗应尽可能保守,以防止后续手术干预进一步骨化。
{"title":"Heterotopic mesenteric ossification: a report of two cases.","authors":"Hisham F Bahmad,&nbsp;Olga Lopez,&nbsp;Tyson Sutherland,&nbsp;Marisa Vinas,&nbsp;Kfir Ben-David,&nbsp;Lydia Howard,&nbsp;Robert Poppiti,&nbsp;Sarah Alghamdi","doi":"10.4132/jptm.2022.07.23","DOIUrl":"https://doi.org/10.4132/jptm.2022.07.23","url":null,"abstract":"<p><p>Heterotopic mesenteric ossification (HMO) is abnormal bone formation in tissues which usually do not undergo ossification. There are approximately 75 cases reported worldwide. We present two cases of HMO. The first case is that of a 39-year-old man who presented with abdominal pain and a computerized tomography scan of the abdomen and pelvis revealed an apple core lesion resulting in small bowel obstruction. The second case is that of a 36-year-old woman who presented 2 months after undergoing robotic gastric sleeve resection complaining of weakness and emesis. An esophagogram revealed kinking at the distal esophagus. Surgical resection was performed in both, yielding the diagnosis of HMO. There are various theories as to the pathophysiology of HMO, but no clearly defined mechanism has been established. Management should be conservative whenever possible to prevent further ossification with subsequent surgical intervention.</p>","PeriodicalId":46933,"journal":{"name":"Journal of Pathology and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/34/jptm-2022-07-23.PMC9510041.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pathology and Translational Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1